Your support fuels our research to #EndALS! Donate Now


TDI 168

Scientists at the ALS Therapy Development Institute are testing this small molecule to address the oxidative stress observed in the cells of PALS.


Type: Small Molecule
Stage: Preclinical
Status: Active
Sponsor: ALS Therapy Development Institute

TDI Says:

Our team is working to finalize the formulation strategy that will be used throughout the preclinical testing of this compound. 

Comment on this Topic

(All comments are moderated before they appear here.)